Teaching tolerance: New approaches to enzyme replacement therapy for Pompe disease

Area of Science:

• Immunology
• Biotechnology
• Pediatric Medicine

Background:

• Pompe disease requires lifelong enzyme-replacement therapy (ERT) using recombinant human lysosomal acid α-glucosidase (rhGAA).
• ERT efficacy is often compromised by the development of high-titer anti-drug antibodies (ADA) against rhGAA, leading to treatment failure and poor outcomes, especially in CRIM-negative infants.
• Current strategies involving immunosuppressants to manage ADA have unknown long-term effects, necessitating alternative approaches for inducing immune tolerance.

Purpose of the Study:

• To explore alternative strategies for inducing antigen-specific immune tolerance to rhGAA in Pompe disease.
• To investigate the potential of Tregitopes, derived from immunoglobulin G (IgG), to induce antigen-specific regulatory T cells (Tregs).
• To evaluate the feasibility of co-delivering rhGAA with Tregitopes as a novel therapeutic approach for CRIM-negative Pompe disease.

Main Methods:

• Investigated the use of Tregitopes, which are natural T cell epitopes known to expand and activate regulatory T cells (Tregs).
• Proposed a strategy of co-delivering rhGAA with Tregitope peptides.
• Focused on inducing antigen-specific tolerance to rhGAA, particularly in the context of CRIM-negative Pompe disease.

Main Results:

• Tregitopes have the capacity to induce antigen-specific regulatory T cells (Tregs).
• Co-administration of rhGAA with Tregitopes is hypothesized to promote immune tolerance.
• This approach could mitigate ADA development and improve ERT effectiveness.

Conclusions:

• Co-delivery of rhGAA with Tregitope peptides offers a promising strategy for inducing immune tolerance in CRIM-negative Pompe disease.
• This novel approach may significantly improve treatment outcomes for infants with Pompe disease by preventing or reducing ADA formation.
• The Tregitope-based strategy holds potential for application in other enzyme replacement therapies complicated by ADA development.